Shire Comments on USPTO Petitions Related to LIALDA and GATTEX

Shire Pharmaceuticals Group Plc [Pressemappe]
Lexington, Massachusetts (ots/PRNewswire) – Shire plc acknowledges the two petitions filed with the U.S. Patent and Trademark Office (USPTO) on April 2nd by Hayman Capital Management regarding LIALDA(R) (mesalamine) and GATTEX(R) (teduglutide [rDNA … Lesen Sie hier weiter…

Ähnliche Beiträge:

  • Shire Comments on AbbVie’s Unchanged Proposal
  • Shire Added to Global 100 Sustainability Index
  • Shire Announces FDA Approval of Manufacturing Facility for…
  • Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII)…
  • PLShire to Acquire NPS Pharma as Further Step in Building a…

Leave a reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>